Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Martín E. Fernández-Zapico

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8089-3907; OpenAlex author ID A5072437086; NIH RePORTER profile ID 8543726. Sources: funder_awards.

Their work

Papers
54 (first author 10, last author 18)
Trials
0
Grants
6
Labs led
1
Collaborators
194
Papers, trials and grants by year

2007: 1 grant · 2008: none · 2009: none · 2010: none · 2011: 3 papers · 2012: 4 papers · 2013: 2 papers · 2014: 3 papers · 2015: 3 papers · 2016: 4 papers · 2017: none · 2018: 4 papers, 1 grant · 2019: 1 paper, 2 grants · 2020: 6 papers, 1 grant · 2021: 3 papers · 2022: 2 papers · 2023: 3 papers · 2024: 5 papers · 2025: 6 papers · 2026: 5 papers, 1 grant

Papers 50 of 54

  1. Nuclear VAV1 increases GLI1-dependent transcription in pancreatic cancer cells. Last author DOI 10.1016/j.jbc.2025.110988↗
  2. A Novel Emerin/Nesprin-3 Interaction Mediates Nuclear Size Changes Induced by Oncogenic KRAS in Pancreatic Cancer Cells. Last author DOI 10.1080/10985549.2026.2670710↗
  3. Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0823↗
  4. Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection. Co-author DOI 10.1158/1078-0432.ccr-25-4968↗
  5. A KLF5's domino effect drives metastatic pancreatic cancer. First author DOI 10.1186/s12943-026-02606-9↗
  6. Novel DAG-Lactone-Based Vav1 Inhibitors Show Anti-proliferative Activity in Pancreatic Cancer Models. Co-author DOI 10.1002/cmdc.202500589↗
  7. The multi-faceted roles of cancer-associated fibroblasts in pancreatic cancer. Last author DOI 10.1016/j.cellsig.2024.111584↗
  8. Paracrine regulation of pancreatic cancer cell response to chemotherapy by GLI2-collagen I signaling. Last author DOI 10.1016/j.jbc.2025.110311↗
  9. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Co-author DOI 10.1073/pnas.2424051122↗
  10. Novel inhibitory effect of Omega-3 fatty acids regulating pancreatic cancer progression. Co-author DOI 10.1093/carcin/bgae081↗
  11. Emerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer. Last author DOI 10.1172/jci.insight.187799↗
  12. Epigenetic regulation of the tumor microenvironment: A leading force driving pancreatic cancer. Last author DOI 10.1016/j.pan.2024.07.005↗
  13. Reconstitution of human PDAC using primary cells reveals oncogenic transcriptomic features at tumor onset. Co-author DOI 10.1038/s41467-024-45097-2↗
  14. Insights into the mechanisms driven by H3K4 KMTs in pancreatic cancer. Last author DOI 10.1042/bcj20230374↗
  15. Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression. Co-author DOI 10.1158/2159-8290.cd-23-0240↗
  16. Rutinosides-derived from Sarocladium strictum 6-O-α-rhamnosyl-β-glucosidase show enhanced anti-tumoral activity in pancreatic cancer cells. Co-author DOI 10.1186/s12934-024-02395-0↗
  17. EGFR Reloaded: Finding New Ways to Shape Pancreatic Cancer Epigenome. First author DOI 10.1016/j.jcmgh.2023.02.003↗
  18. SUFU promotes GLI activity in a Hedgehog-independent manner in pancreatic cancer. Last author DOI 10.1042/bcj20220439↗
  19. GLI1 interaction with p300 modulates SDF1 expression in cancer-associated fibroblasts to promote pancreatic cancer cells migration. Last author DOI 10.1042/bcj20220521↗
  20. Anticachectic regulator analysis reveals Perp-dependent antitumorigenic properties of 3-methyladenine in pancreatic cancer. Co-author DOI 10.1172/jci.insight.153842↗
  21. Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients. Last author DOI 10.15252/emmm.202215707↗
  22. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition. Last author DOI 10.1016/j.jbc.2021.100634↗
  23. PI3Kα targeting, nipping pancreatic cancer evolution in the bud. First author DOI 10.15252/emmm.202114362↗
  24. Nuclear Dynamics and Chromatin Structure: Implications for Pancreatic Cancer. Last author DOI 10.3390/cells10102624↗
  25. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Last author DOI 10.1016/j.pan.2019.11.011↗
  26. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Last author DOI 10.1016/j.pan.2020.06.015↗
  27. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancrea… Co-author DOI 10.1053/j.gastro.2019.10.038↗
  28. Targeting tumour microenvironment, a FAKtual challenge in pancreatic cancer. First author DOI 10.1136/gutjnl-2019-318962↗
  29. It Takes a Village to Overcome KRAS Dependence in Pancreatic Cancer. First author DOI 10.1158/2159-8290.cd-20-0490↗
  30. Stromal deactivation by CSF1: a new feature of the aggressive pancreatic cancer microenvironment. First author DOI 10.15252/embr.202050468↗
  31. Toward personalized TGFβ inhibition for pancreatic cancer. First author DOI 10.15252/emmm.201911414↗
  32. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Co-author DOI 10.1073/pnas.1722434115↗
  33. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Co-author DOI 10.1158/1055-9965.epi-17-1065↗
  34. ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. Co-author DOI 10.1158/1078-0432.ccr-18-0263↗
  35. Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes? Last author DOI 10.3390/cancers10050128↗
  36. Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence. First author DOI 10.1053/j.gastro.2016.06.032↗
  37. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-15-2068↗
  38. Pancreatic cancer microenvironment, to target or not to target? First author DOI 10.15252/emmm.201505948↗
  39. Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language. Last author PMID 28018146↗
  40. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/ijc.29242↗
  41. Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. Co-author DOI 10.1093/carcin/bgv058↗
  42. Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion. Co-author DOI 10.1158/0008-5472.can-14-3103↗
  43. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccr.2014.04.021↗
  44. Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression. Last author DOI 10.1074/jbc.m113.539031↗
  45. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Co-author DOI 10.1158/2159-8290.cd-13-0593↗
  46. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. Co-author DOI 10.1002/emmm.201302507↗
  47. Mechanistic insights into self-reinforcing processes driving abnormal histogenesis during the development of pancreatic cancer. Co-author DOI 10.1016/j.ajpath.2012.12.004↗
  48. Aberrant signaling pathways in pancreatic cancer: a two compartment view. Last author DOI 10.1002/mc.20827↗
  49. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Co-author DOI 10.1053/j.gastro.2011.11.001↗
  50. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Co-author DOI 10.1053/j.gastro.2012.08.044↗

Grants 6

  1. New Therapuetics for Pancreatic Cancer R01CA265050↗
  2. Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds R01CA208517↗
  3. Mechanism of Pancreatic Carcinogenesis R01CA136526↗
  4. ZIP4 is a Novel Molecular Target in Human Pancreatic Cancer R01CA186338↗
  5. Administrative Core P50CA102701↗
  6. Characterization of the Hedgehog Interacting Pathway in Pancreatic Cancer AWARD pancan:2007-martin-e-fernandez-zapico-md-characterization-of-the-hedgehog-interac

Closest collaborators

The 25 strongest of 194 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Renzo Emanuel Vera · 10 shared papers, 2020–2026 · strength 2.29
  2. Ezequiel J. Tolosa · 8 shared papers, 2020–2025 · strength 1.44
  3. Kayla C. LaRue-Nolan · 5 shared papers, 2023–2026 · strength 1.42
  4. Mitesh J. Borad · 2 shared papers, 1 shared grant, 2020–2026 · strength 1.16
  5. Ryan Michael Carr · 7 shared papers, 2016–2026 · strength 1.15
  6. Michael T. Barrett · 1 shared grant, 2026 · strength 1.00
  7. Brooke R Tader · 4 shared papers, 2021–2026 · strength 0.91
  8. Luis F. Flores · 4 shared papers, 2021–2026 · strength 0.79
  9. Gloria M. Petersen · 4 shared papers, 2 shared grants, 2012–2021 · strength 0.76
  10. Glancis L. Raja Arul · 3 shared papers, 2021–2024 · strength 0.72
  11. Nicole M. Pena Ruiz · 1 shared paper, 2026 · strength 0.63
  12. David R Pease · 3 shared papers, 2023–2025 · strength 0.55
  13. Daniel D. Billadeau · 4 shared papers, 1 shared grant, 2011–2026 · strength 0.53
  14. Jiaqi Shi · 2 shared papers, 2024–2026 · strength 0.49
  15. Robert R. McWilliams · 6 shared papers, 2012–2026 · strength 0.49
  16. Hu Li · 1 shared paper, 1 shared grant, 2020–2021 · strength 0.48
  17. Mark Joseph Truty · 2 shared papers, 2026 · strength 0.44
  18. John Y. Kwon · 1 shared paper, 2025 · strength 0.42
  19. Min Li · 1 shared grant, 2019 · strength 0.40
  20. Thomas C. Smyrk · 4 shared papers, 1 shared grant, 2012–2020 · strength 0.37
  21. David W. Dawson · 2 shared papers, 2016–2025 · strength 0.31
  22. Brooke D. Paradise · 2 shared papers, 2018–2023 · strength 0.30
  23. Rondell Patrell Graham · 2 shared papers, 2020–2025 · strength 0.28
  24. Judith Vinaixa · 2 shared papers, 2018–2025 · strength 0.27
  25. Neus Martínez‐Bosch · 2 shared papers, 2018–2025 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.